Gut microbial metabolites SCFAs and chronic kidney disease

J Transl Med. 2024 Feb 18;22(1):172. doi: 10.1186/s12967-024-04974-6.

Abstract

The global incidence of Chronic Kidney Disease (CKD) is steadily escalating, with discernible linkage to the intricate terrain of intestinal microecology. The intestinal microbiota orchestrates a dynamic equilibrium in the organism, metabolizing dietary-derived compounds, a process which profoundly impacts human health. Among these compounds, short-chain fatty acids (SCFAs), which result from microbial metabolic processes, play a versatile role in influencing host energy homeostasis, immune function, and intermicrobial signaling, etc. SCFAs emerge as pivotal risk factors influencing CKD's development and prognosis. This paper review elucidates the impact of gut microbial metabolites, specifically SCFAs, on CKD, highlighting their role in modulating host inflammatory responses, oxidative stress, cellular autophagy, the immune milieu, and signaling cascades. An in-depth comprehension of the interplay between SCFAs and kidney disease pathogenesis may pave the way for their utilization as biomarkers for CKD progression and prognosis or as novel adjunctive therapeutic strategies.

Keywords: CKD; Gut microbial metabolites; Inflammatory responses; Oxidative stress; SCFAs.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Fatty Acids, Volatile / metabolism
  • Fatty Acids, Volatile / therapeutic use
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Renal Insufficiency, Chronic* / drug therapy
  • Signal Transduction

Substances

  • Fatty Acids, Volatile
  • Biomarkers